20
Views
19
CrossRef citations to date
0
Altmetric
Research Article

Synergistic Cytotoxicity of Recombinant Human TNF and Various Anti-Cancer Drugs

, , , , , , & show all
Pages 117-127 | Published online: 28 Sep 2008

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

S. P. Prete, R. De Filippi, E. Silvi, A. Bartocci & A. Giuliani. (1990) Role of Vincristine in Immunochemotherapy of Leukemia in Mouse or Human Models. Immunopharmacology and Immunotoxicology 12:1, pages 135-157.
Read now

Articles from other publishers (18)

Kamarudin N. H.Bachek N. F.Mohd Hezmee Mohd Noor. (2021) Modulation of C5a-C5aR interactions against murine mammary cancer cell line. Comparative Clinical Pathology 30:3, pages 549-557.
Crossref
R R Weichselbaum & D Kufe. (2009) Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers. Cancer Gene Therapy 16:8, pages 609-619.
Crossref
Dong-Oh Moon, Mun-Ock Kim, Sang-Hyuck Kang, Yung Hyun Choi & Gi-Young Kim. (2009) Sulforaphane suppresses TNF-α-mediated activation of NF-κB and induces apoptosis through activation of reactive oxygen species-dependent caspase-3. Cancer Letters 274:1, pages 132-142.
Crossref
Holly J. Meany, Nita L. Seibel, Junfeng Sun, Jerry Z. Finklestein, Judith Sato, John Kelleher, Paul Sondel & Gregory Reaman. (2008) Phase 2 Trial of Recombinant Tumor Necrosis Factor-α in Combination With Dactinomycin in Children With Recurrent Wilms Tumor. Journal of Immunotherapy 31:7, pages 679-683.
Crossref
Remco van Horssen, Timo L. M. ten Hagen & Alexander M. M. Eggermont. (2006) TNF-α in Cancer Treatment: Molecular Insights, Antitumor Effects, and Clinical Utility. The Oncologist 11:4, pages 397-408.
Crossref
Carlo Riccardo Rossi, Simone Mocellin, Pierluigi Pilati, Mirto Foletto, Luca Campana, Luigi Quintieri, Gian Luca De Salvo & Mario Lise. (2005) Hyperthermic Isolated Perfusion With Low-Dose Tumor Necrosis Factor α and Doxorubicin for the Treatment of Limb-Threatening Soft Tissue Sarcomas. Annals of Surgical Oncology 12:5, pages 398-405.
Crossref
Timo L. M. ten Hagen & A. M. M. Eggermont. (2016) Solid Tumor Therapy: Manipulation of the Vasculature with TNF. Technology in Cancer Research & Treatment 2:3, pages 195-203.
Crossref
P Österlund, A Orpana, I Elomaa, H Repo & H Joensuu. (2002) Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma. British Journal of Cancer 87:6, pages 591-599.
Crossref
Nobuo Suzuki, Souei Sekiya, Isamu Sugano, Takayuki Kojima, Hideo Yamamori & Yoshiaki Takakubo. (2005) Dipyridamole Combined with Tumor Necrosis Factor‐α Enhances Inhibition of Proliferation in Human Tumor Cell Lines. Japanese Journal of Cancer Research 86:8, pages 761-769.
Crossref
Naoki Watanabe, Tetsuro Okamoto, Naoki Tsuji, Hiroyoshi Sasaki, Shinichiro Akiyama, Daisuke Kobayashi, Tsutomu Sato, Naofumi Yamauchi & Yoshiro Niitsu. (2005) Reversal of Tumor Necrosis Factor Resistance in Tumor Cells by Adriamycin via Suppression of Intracellular Resistance Factors. Japanese Journal of Cancer Research 86:4, pages 395-399.
Crossref
Jes�s Vaquero, Mercedes Zurita & Santiago Oya. (1995) Growth-inhibiting effect of intratumoral recombinant human tumor necrosis factor on an experimental model of primitive neuroectodermal tumor. Journal of Neuro-Oncology 23:1, pages 9-14.
Crossref
Mercedes Zurita, Maria del Mar Cabrera, Carmen Morales, Santiago Oya & Jesús Vaquero. (1994) Influence of the postnatal administration of tumor necrosis factor plus interferon-α2b on the developments of ethyl-nitrosourea-induced brain tumors in rats. Neuroscience Letters 174:2, pages 213-216.
Crossref
Yoichi Mizutani & Benjamin Bonavida. (1993) Overcoming cis-diamminedichloroplatinum (II) resistance of human ovarian tumor cells by combination treatment with cis-diamminedichloroplatinum (II) and tumor necrosis factor–alpha. Cancer 72:3, pages 809-818.
Crossref
Jeffrey Taylor Safrit, Arie Belldegrun & Benjamin Bonavida. (1993) Sensitivity of Human Renal Cell Carcinoma Lines to TNF, Adriamycin, and Combination: Role of TNF mRNA Induction in Overcoming Resistance. Journal of Urology 149:5 Part 1, pages 1202-1208.
Crossref
Rajinder S. Sidhu & Arthur P. Bollon. (1993) Tumor necrosis factor activities and cancer therapy — A perspective. Pharmacology & Therapeutics 57:1, pages 79-128.
Crossref
Candace S. Johnson, Ming-Jei Chang, Wei-Dong Yu, Ruth A. Modzelewski, Jennifer R. Grandis, Daniel R. Vlock & Philip Furmanski. (1993) Synergistic enhancement by interleukin-1 ? of cisplatin-mediated antitumor activity in RIF-1 tumor-bearing C3H/HeJ mice. Cancer Chemotherapy and Pharmacology 32:5, pages 339-346.
Crossref
Jürgen C. W. Kiwit, Karl-Heinz Schmitz, Ludwig Daum, Guido Reifenberger & Norbert Roosen. (1991) Effects of recombinant human tumor necrosis factor on rodent gliomas and normal brain. Journal of Neurosurgery 75:4, pages 597-603.
Crossref
J. Baumgart, B. Schlott, J. Suehnel, W. Vater, W. Schulze & D. Behnke. (1991) Synergistic cytotoxicity of human recombinant tumour necrosis factor α combined with microtubule effectors. Journal of Cancer Research and Clinical Oncology 117:3, pages 239-243.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.